Evidence map›Paper›PMID 37013911›Full record

ArticleMolecular oncology2023

Comprehensive profiling of pathogenic germline large genomic rearrangements in a pan-cancer analysis.

Zhe Sun, Chujie Bai, Miaoyi Su, Haimeng Tang, Xiaoying Wu, Yue Wang, Hua Bao, Xunbiao Liu, Xue Wu, Yang Shao and 1 more

Open access · goldAbstract read
In one paragraph

Article in Molecular oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.7field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Observational
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 2 countries.

Zhe SunThe First Clinical Medical College, Guangzhou University of Chinese Medicine, Guangdong, China.
Chujie BaiDepartment of Bone and Soft Tissue Tumor, Key Laboratory of Carcinogenesis and Translational Research, Peking University Cancer Hospital and Institute, Beijing, China.
Miaoyi SuDepartment of Radiation Oncology, Guangqian Hospital, Quanzhou, China.
Haimeng TangGeneseeq Research Institute, Nanjing Geneseeq Technology Inc., China.ORCID 0000-0002-7519-8213
Xiaoying WuGeneseeq Research Institute, Nanjing Geneseeq Technology Inc., China.
Yue WangGeneseeq Research Institute, Nanjing Geneseeq Technology Inc., China.ORCID 0000-0002-1002-6031
Hua BaoGeneseeq Research Institute, Nanjing Geneseeq Technology Inc., China.
Xunbiao LiuGeneseeq Research Institute, Nanjing Geneseeq Technology Inc., China.
Xue WuGeneseeq Research Institute, Nanjing Geneseeq Technology Inc., China.
Yang ShaoGeneseeq Research Institute, Nanjing Geneseeq Technology Inc., China.
Bei XuDepartment of Medical Oncology, Zhongshan Hospital, Shanghai, China.
Guangzhou University of Chinese Medicine · CNNanjing Medical University · CNPeking University · CNThe 180th Hospital of PLA · CNZhongshan Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The presence of large genomic rearrangements (LGRs) has been heavily investigated in breast and ovarian cancer. However, correlations between LGRs and cancer types beyond these two have not been extensively profiled, likely due to the highly inefficient methods of detecting these types of alterations. This study utilized next-generation sequencing (NGS) to analyze and classify the germline LGR profile in 17 025 cancer patients across 22 cancer types. We characterized newly identified LGRs based on predicted pathogenicity and took a closer look at genes that acquire both germline and somatic mutations within our samples. The detection method for LGRs was validated using droplet digital polymerase chain reaction (ddPCR) assay of commonly investigated LGR genes. In total, 15 659 samples from across 22 cancer types were retained for analysis after filtering. We observed that, in our cohort, the cancer types with the highest proportion of germline LGRs were ovarian cancer (4.7%), renal cell carcinoma (2.5%), breast cancer (2%), glioma (1.8%) and thyroid carcinoma (1.8%). Annotation of detected germline variants revealed several genes-MSH2, FANCA and PMS2-that contain novel LGRs. We observed co-occurrences between germline LGRs in MSH2 and somatic single nucleotide variants/insertion and deletions (SNVs/InDels) in BRCA2, KTM2B, KDM5A, CHD8, and HNF1A. Furthermore, our analysis showed that samples with pathogenic and likely pathogenic germline LGRs tended to also have higher mutational burden, chromosomal instability, and microsatellite instability ratio compared to samples with pathogenic germline SNVs/InDels. In this study, we demonstrated the prevalence of pathogenic germline LGRs beyond breast and ovarian cancer. The profiles of these pathogenic or likely pathogenic alterations will fuel further investigations and highlight new understanding of LGRs across multiple cancer types.

Indexed as

Breast NeoplasmsOvarian NeoplasmsFemaleGene RearrangementGenomicsGerm CellsGerm-Line MutationHumansMutS Homolog 2 ProteinRetinoblastoma-Binding Protein 2KDM5A protein, humanMutS Homolog 2 ProteinRetinoblastoma-Binding Protein 2double-hit hypothesislarge genomic rearrangementnext generation sequencingpathogenic germline mutation

Identifiers

PMID37013911
PMCPMC10483597
OpenAlexW4362521000

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.